Form 8-K - Current report:
SEC Accession No. 0001745020-23-000006
Filing Date
2023-05-11
Accepted
2023-05-11 07:09:30
Documents
13
Period of Report
2023-05-11
Items
Item 2.02: Results of Operations and Financial Condition

Document Format Files

Seq Description Document Type Size
1 8-K thrx-20230511.htm   iXBRL 8-K 37382
2 EX-99.1 thrx-20230331xexx991.htm EX-99.1 61434
  Complete submission text file 0001745020-23-000006.txt   248831

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT thrx-20230511.xsd EX-101.SCH 1893
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT thrx-20230511_lab.xml EX-101.LAB 24831
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT thrx-20230511_pre.xml EX-101.PRE 13037
7 EXTRACTED XBRL INSTANCE DOCUMENT thrx-20230511_htm.xml XML 11989
Mailing Address 314 MAIN STREET, SUITE 04-200 CAMBRIDGE MA 02142
Business Address 314 MAIN STREET, SUITE 04-200 CAMBRIDGE MA 02142 (857) 400-9491
Theseus Pharmaceuticals, Inc. (Filer) CIK: 0001745020 (see all company filings)

EIN.: 830712806 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40869 | Film No.: 23908774
SIC: 2834 Pharmaceutical Preparations